Back
Elite Pharmaceuticals 10K Form
Sell
27
ELTP
Elite Pharmaceuticals
Last Price:
$0.59
Seasonality Move:
1.07%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2021-02-16 | 10Q | ELTP/Elite Pharmaceuticals Quarterly |
2020-11-16 | 10Q | ELTP/Elite Pharmaceuticals Quarterly |
2020-08-14 | 10Q | ELTP/Elite Pharmaceuticals Quarterly |
2020-06-29 | 10K | ELTP/Elite Pharmaceuticals Annual |
2020-02-10 | 10Q | ELTP/Elite Pharmaceuticals Quarterly |
2019-11-12 | 10Q | ELTP/Elite Pharmaceuticals Quarterly |
Receive ELTP News And Ratings
See the #1 stock for the next 7 days that we like better than ELTP
ELTP Financial Statistics
Sales & Book Value
Annual Sales: | $84M |
---|---|
Cash Flow: | $-1.1M |
Price / Cash Flow: | 130 |
Annual Sales: | $0.03 |
Price / Book: | 11.96 |
Profitability
EPS (TTM): | -0.01940 |
---|---|
Net Income (TTM): | $-18M |
Gross Margin: | $40.1M |
Return on Equity: | -36.56% |
Return on Assets: | -21.15% |
Elite Pharmaceuticals Earnings Forecast
Key Elite Pharmaceuticals Financial Ratios
-
The Gross Profit Margin over the past 19 years for ELTP is 47.70%.
-
The Selling, General & Administrative Expenses for ELTP have been equal to 10.98% of Gross Profit Margin.
-
The Research & Development expenses have been 9.48% of Revenue.
-
The Net Earning history of ELTP is -5.13% of Total Revenues.
-
Per Share Earnings over the last 27 years have been positive in 12 years.
Elite Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | OTCM |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | ELTP |
Website: | elitepharma.com |
Debt
Debt-to-Equity Ratio: | 0.2 |
---|---|
Current Ratio: | 3.27 |
Quick Ratio: | 1.82 |
Price-to-Earnings
Trailing P/E Ratio: | 36.6 |
---|---|
Forward P/E Ratio: | 0 |
ELTP Technical Analysis vs Fundamental Analysis
Sell
27
Elite Pharmaceuticals (ELTP)
is a Sell
Is Elite Pharmaceuticals a Buy or a Sell?
-
Elite Pharmaceuticals stock is rated a SellThe current Elite Pharmaceuticals [ELTP] share price is $0.59. The Score for ELTP is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.